Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


National trends and perioperative outcomes of robotic resection of thymic tumours in the United States: a propensity matching comparison with open and video-assisted thoracoscopic approaches†.

Kamel MK, Villena-Vargas J, Rahouma M, Lee B, Harrison S, Stiles BM, Abdelrahman AM, Altorki NK, Port JL.

Eur J Cardiothorac Surg. 2019 Oct 1;56(4):762-769. doi: 10.1093/ejcts/ezz111.


Laparoscopic Repair of an Intrapericardial Diaphragmatic Hernia After Convergent Maze Procedure.

Kaufman AJ, Kahn ET, Villena-Vargas J, Steele JG, Flores RM.

Ann Thorac Surg. 2017 Jun;103(6):e541-e543. doi: 10.1016/j.athoracsur.2017.01.033. Epub 2017 Feb 3.


Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS.

J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.


Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration.

Kadota K, Eguchi T, Villena-Vargas J, Woo KM, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Oncotarget. 2015 Sep 29;6(29):27505-18. doi: 10.18632/oncotarget.4752.


Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma.

Kadota K, Buitrago D, Lee MC, Villena-Vargas J, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Lung Cancer. 2015 Sep;89(3):329-36. doi: 10.1016/j.lungcan.2015.06.003. Epub 2015 Jun 15.


Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Kadota K, Yeh YC, Villena-Vargas J, Cherkassky L, Drill EN, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Chest. 2015 Sep;148(3):711-721. doi: 10.1378/chest.14-3005.


Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.

Kadota K, Villena-Vargas J, Nitadori J, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Ann Surg Oncol. 2015 Sep;22(9):3136-43. doi: 10.1245/s10434-015-4374-x. Epub 2015 Jan 22.


Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.

Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162.


Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence.

de Biasi AR, Villena-Vargas J, Adusumilli PS.

Clin Cancer Res. 2014 Nov 1;20(21):5384-91. doi: 10.1158/1078-0432.CCR-14-1298. Epub 2014 Sep 9. Review.


Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, Rusch VW, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2014 Apr;38(4):448-60. doi: 10.1097/PAS.0000000000000134.


Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.

Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS.

Clin Cancer Res. 2014 Feb 15;20(4):1020-8. doi: 10.1158/1078-0432.CCR-13-1862. Epub 2013 Dec 13. Erratum in: Clin Cancer Res. 2014 Jul 15;20(14):3896.


Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.

Villena-Vargas J, Adusumilli PS.

Ann Cardiothorac Surg. 2012 Nov;1(4):466-71. doi: 10.3978/j.issn.2225-319X.2012.10.03. No abstract available.


Safety and stability of retrovirally transduced chimeric antigen receptor T cells.

Colovos C, Villena-Vargas J, Adusumilli PS.

Immunotherapy. 2012 Sep;4(9):899-902. doi: 10.2217/imt.12.91.


Supplemental Content

Loading ...
Support Center